Pharmac proposes funding new blood cancer drugs pomalidomide and lenalidomide for 800+ New Zealanders with multiple myeloma or myelodysplastic syndrome.
Pharmac proposes to fund new blood cancer drug pomalidomide and widen access to lenalidomide, benefiting over 800 New Zealanders with multiple myeloma or myelodysplastic syndrome. This proposal aims to improve patients' quality of life by providing more treatment options. Both treatments work to prevent disease progression and are taken as capsules in combination with other therapies.
April 23, 2024
4 Articles